Chronic coronary syndrome

Article written and reviewed by Dr Luca Moretti

Chronic coronary syndrome is the persistent or stabilized clinical manifestation of coronary artery disease. It includes patients with newly developed but nonacute symptoms, those with previously documented coronary artery disease, people stabilized after myocardial infarction or revascularization, and patients with ventricular dysfunction of ischemic origin. The definition includes both obstructive epicardial stenoses and non-obstructive mechanisms involving the microcirculation or vasospasm. The term “chronic” denotes a continuous process of assessment and prevention, not a condition that has been permanently resolved.
The syndrome arises from the interaction among anatomy, physiology, and vulnerability. A stenosis may limit flow during exertion, but angiographic severity does not perfectly predict ischemia; modest plaques may rupture and cause an acute event. Prognostic risk therefore depends on atherosclerotic burden, ventricular function, and comorbidities as well as symptoms. A person with frequent angina may have relatively low risk, whereas an asymptomatic person with left main disease or reduced ejection fraction may be at high risk. Symptoms and prognosis are treated as distinct objectives.

The diagnostic pathway starts not with a test but with clinical probability. Characteristics of discomfort, age, sex, risk factors, ECG, ventricular function, and vascular disease modify the probability of obstructive coronary artery disease. This determines whether not to test, use CCTA, select functional imaging, or proceed to coronary angiography. Testing must be capable of changing the diagnosis, treatment, or risk assessment. An apparently discordant result requires review of quality and mechanisms, not an automatic sequence of tests.
Therapy integrates event prevention, symptom control, and management of comorbidities. Lipids, smoking, blood pressure, diabetes, activity, and adherence act on the entire arterial tree; antianginal drugs reduce demand or improve flow; PCI and bypass surgery treat selected anatomical patterns. A stent does not replace preventive therapy, and medical therapy does not preclude revascularization when necessary. Decisions are shared by explaining the expected effects on survival, myocardial infarction, angina, and quality of life.

Etiology, risk factors, pathogenesis, and pathophysiology

Atherosclerosis begins with intimal retention of apoB lipoproteins, lipid modification, and an inflammatory response. Plaques grow focally or diffusely, calcify, and remodel the wall; the lumen may remain relatively preserved until advanced stages. LDL and non-HDL reflect atherogenic exposure, whereas lipoprotein(a) adds partly genetically determined atherothrombotic and calcific risk. Smoking, hypertension, diabetes, and kidney disease accelerate endothelial dysfunction, inflammation, and plaque progression.
An epicardial stenosis produces a pressure drop proportional to its geometry and flow. At rest, arteriolar autoregulation may maintain perfusion; during exertion, when resistance vessels are already dilated, reserve is exhausted and ischemia develops. Long and serial lesions and diffuse disease produce gradients different from those of a focal stenosis. FFR during hyperemia and nonhyperemic pressure ratios such as iFR measure functional consequences, but the result must be correlated with symptoms, territory, and the microcirculation.

The microcirculation regulates most coronary resistance. Arteriolar remodeling, rarefaction, perivascular fibrosis, and endothelial dysfunction reduce CFR; microvascular spasm causes dynamic constriction. Diabetes, hypertrophy, inflammation, and menopause may contribute without defining the diagnosis by themselves. Dysfunction may coexist with a stenosis and explain angina after apparently successful PCI. Low CFR combines epicardial and microvascular components; resistance indices and vasoactive testing help separate endotypes.
Myocardial demand rises with heart rate, contractility, and wall tension. Hypertension and dilatation increase the cost of each systole; tachycardia shortens diastole, during which left coronary perfusion predominates. Anemia and hypoxia reduce arterial oxygen content. Beta-blockade, afterload reduction, and exercise training may raise the ischemic threshold without changing the plaque. The threshold varies from day to day with temperature, meals, autonomic stress, sleep, and medication intake.

Ischemia causes ATP depletion, metabolite accumulation, impaired relaxation, and then systolic dysfunction. ECG changes and pain appear later in the ischemic cascade, although the sequence is not rigid. Diffuse ischemia may not produce a clear regional abnormality and may reduce the sensitivity of some methods; prolonged episodes cause necrosis, repeated episodes cause stunning, and chronic hypoperfusion may contribute to hibernation. Scar and remodeling become substrates for heart failure and arrhythmias even when angina disappears.
Plaque vulnerability explains why a chronic syndrome may destabilize. Rupture, erosion, and thrombosis depend on plaque composition and inflammation as well as stenosis severity; many infarct-related lesions were not previously severe. Statins, smoking cessation, and risk-factor control reduce risk across the entire vascular bed. PCI corrects a focal flow problem, whereas prevention treats the diffuse process responsible for new coronary, cerebral, and peripheral events.

Nonatherosclerotic factors include vasospasm, myocardial bridging, coronary anomalies, sequelae of dissection, and vasculitis. A bridge may compress the intramyocardial segment, particularly with tachycardia and short diastole, but its frequent anatomical presence does not imply causality. Diagnosis requires concordance among physiology, symptoms, and territory. Treatment cannot be copied from atherosclerotic stenosis: nitrates may worsen some bridges, whereas calcium channel blockers are central in vasospasm.
The collateral circulation develops in response to chronic gradients and may preserve viability at rest but rarely fully normalizes reserve during exertion. Its presence explains tolerance of some occlusions and changes procedural risk because a collateral may depend on the treated vessel. Angiography describes size and connections, whereas physiology assesses consequences. The decision to recanalize a CTO considers symptoms, ischemia, viability, complexity, and probability of success.

Endothelial function integrates lipids, smoking, blood pressure, and inflammation. Impaired vasodilation or paradoxical constriction reduces flow and promotes thrombosis; exercise, statins, and risk-factor control may improve it. Vasomotor function varies among segments and over time. A fixed stenosis and spasm may coexist in the same vessel; this overlap explains episodes at rest in patients with exertional angina and requires combined therapy.

Pathological anatomy, classification, and progression

Disease may be non-obstructive, focally obstructive, multivessel, or diffuse. The left main and proximal left anterior descending arteries supply large territories; dominance changes the myocardial mass at risk. The SYNTAX score describes angiographic complexity but does not replace age, diabetes, ejection fraction, frailty, and operative risk. Calcification, bifurcations, chronic occlusions, and small vessels affect PCI feasibility. Bypass surgery creates alternative conduits, but graft patency and progression in native vessels determine the subsequent course.
Clinical scenarios include suspected coronary artery disease with stable symptoms, ischemic heart failure, the stabilized phase after ACS or revascularization, long-standing disease, and ANOCA/INOCA. Each scenario has a different probability and diagnostic question. After ACS, thrombotic risk and DAPT duration are central; in long-standing disease, prevention, symptoms, and clinical surveillance predominate. In non-obstructive disease, functional diagnosis is needed instead of repeated angiography that provides no information about the mechanism.

Anatomical extent does not coincide with ischemic burden. A severe stenosis with collateral vessels may be well tolerated; moderate diffuse disease and microvascular dysfunction may substantially reduce reserve. Quantitative PET and CMR detect global reductions that regional comparisons may underestimate. FFR assesses the vessel during hyperemia and iFR during a resting diastolic window. Discordances are not automatically errors but expressions of different physiologies that must be integrated.
Plaques evolve through growth, intraplaque hemorrhage, calcification, and possible episodes of subclinical thrombosis with healing. Therapy may stabilize plaque composition and reduce lipid content while the lumen changes little. Coronary calcium tends to increase even with statin therapy and is not used alone to judge treatment failure. Clinical progression is assessed through events, symptoms, function, and targets, not by repeating the calcium score in a patient with known disease.

After myocardial infarction, necrosis is replaced by scar; the ventricle may dilate and become less efficient. Residual ischemia, functional mitral regurgitation, and arrhythmias worsen the presentation. Functional recovery after reperfusion or therapy indicates stunning or reverse remodeling, not elimination of risk. Ejection fraction is reassessed after an appropriate interval before device decisions. CMR quantifies scar and viable tissue when this information changes the strategy.
After PCI, restenosis generally presents with a progressive return of symptoms, whereas stent thrombosis may present as an acute event. After bypass surgery, venous graft stenosis and progression in native vessels increase over time; internal mammary grafts have different durability. Post-revascularization pain does not prove mechanical failure: microvascular dysfunction, vasospasm, and noncardiac causes are common. Anatomy is reassessed when probability and therapeutic consequences justify testing.

The trajectory is modified by adherence, access to care, frailty, and comorbidities. Kidney disease increases calcification, bleeding, and limitations related to contrast; diabetes promotes diffuse and microvascular disease; cancer may alter thrombosis and priorities. In older adults, autonomy and life expectancy are integrated with procedural risk without using age as the only criterion. Follow-up is not merely coronary surveillance but longitudinal management of the person.
The diffuse disease phenotype may be recognized by long narrowing, reduced caliber, and a progressive physiological gradient. It does not always offer a focal target for PCI and makes preventive and antianginal therapy more important. Bypass surgery may circumvent long segments if an adequate distal target exists. Diffuse plaque increases systemic risk even when no stenosis exceeds a conventional threshold.

Calcified plaques may require calcium modification using dedicated techniques before stenting. Insufficient preparation causes underexpansion, whereas aggressive treatment increases dissection and perforation. Imaging defines arc and depth and guides diameter; technical complexity contributes to the choice between PCI and bypass surgery. A feasible procedure is not automatically preferable if the likelihood of completeness or durability is low.

Clinical manifestations

The classic symptom is deep, pressing, or constricting chest discomfort brought on by exertion, cold, a meal, or stress and relieved within a few minutes by rest. Radiation to the arm, shoulder, jaw, back, or epigastrium is common but not required. Burning does not exclude angina, whereas pinpoint localization makes it less likely. Reproducibility of the threshold is informative; recent changes require exclusion of instability.
Exertional dyspnea may be an ischemic equivalent, a consequence of transient diastolic dysfunction, or a sign of heart failure. It must be distinguished from chronic lung disease, anemia, obesity, deconditioning, and pulmonary hypertension. Fatigue and reduced capacity have low specificity, but a reproducible change with workload increases suspicion. An activity diary clarifies what the patient can no longer do and what is being avoided.

The CCS classification measures functional limitation: class I for angina only during strenuous exertion, II for slight limitation, III for marked limitation, and IV for inability to perform activity without symptoms or angina at rest. It does not measure ischemia, anatomy, or prognosis. The class may improve because the patient reduces activity, so it must be paired with functional assessment. The Seattle Angina Questionnaire quantifies frequency, limitation, quality of life, and treatment satisfaction.
In diabetes and older age, atypical symptoms or absence of pain may predominate because of neuropathy, perceptual threshold, and comorbidities. Women more frequently have non-obstructive mechanisms but also develop epicardial coronary disease and must not automatically be directed toward functional diagnoses. Probability is calculated without stereotypes. Palpitations or syncope during exertion require assessment for arrhythmias, aortic stenosis, and cardiomyopathies as well as ischemia.

A normal examination does not exclude the syndrome. Signs of systemic atherosclerosis, carotid bruits, reduced pulses, or a low ankle-brachial index increase risk; xanthomas suggest severe dyslipidemia. Crackles, a third heart sound, jugular venous distention, and edema indicate heart failure; an aortic or mitral murmur may explain or worsen symptoms. Blood pressure in both arms, heart rate, and orthostatic hypotension must be assessed before titrating antianginal drugs.
Prolonged pain at rest, rapid crescendo, sweating, syncope, hypotension, or acute dyspnea shifts the presentation toward acute coronary syndrome. ECG and troponin testing are not delayed because the patient has a known chronic diagnosis. A slower reduction in threshold may result from progression, restenosis, anemia, arrhythmia, or missed medication. Change from baseline is often more informative than absolute intensity.

Quality of life is affected by fear of exertion, depression, insomnia, and occupational restrictions. These factors may amplify symptoms and reduce adherence but do not replace investigation for ischemia. A clear explanation of the role of medications, the safety of activity, and warning signs reduces avoidance. Rehabilitation provides a supervised environment in which to restore capacity, assess the threshold, and address psychosocial determinants.
In patients with kidney disease, neuropathy, or diabetes, presentation may be paucisymptomatic. Dyspnea, functional decline, and congestion require comparison with baseline. Persistent troponin elevation may indicate chronic myocardial injury and must be interpreted in context, whereas a dynamic change documents acute injury. Concurrent causes become more frequent with comorbidities. A careful pathway avoids both missing ischemia and attributing every symptom to known coronary disease.

After revascularization, the meaning of pain depends on timing. In the first hours, occlusion and complications are excluded; over subsequent weeks, healing, the pericardium, and adaptation become relevant; months or years later, restenosis, graft disease, and progression become more plausible. Nonischemic post-sternotomy chest pain may persist. Describing the new symptom in relation to the previous one improves diagnostic precision.

Investigations and diagnosis

The history establishes duration, triggers, threshold, radiation, response to nitrate, and recent changes. Resting ECG may show Q waves, ST-T abnormalities, conduction block, or hypertrophy but may be normal. Complete blood count, creatinine, electrolytes, HbA1c, and lipids identify precipitants, safety issues, and targets. Echocardiography assesses ejection fraction, wall motion, valves, and alternative diagnoses. Chest radiography, TSH, spirometry, or other tests are guided by the presentation and are not included automatically.
Clinical probability of obstructive coronary artery disease uses age, sex, and the nature of symptoms, then is modified by risk factors, ECG, dysfunction, vascular disease, and coronary calcium. Historical estimates overestimated contemporary prevalence and produced many false positives. With very low probability, coronary imaging may be unnecessary. With low or intermediate probability, CCTA is often the first choice; with high probability or known coronary disease, functional testing may answer the question better.

CCTA describes stenoses, calcified and noncalcified plaque, remodeling, and anatomy. Quality requires controllable heart rate, breath-holding, and contrast. Extensive calcium causes blooming and may overestimate narrowing; a high-quality negative result has strong rule-out value. Intermediate stenoses or non-evaluable segments require integration with FFR-CT, stress imaging, or coronary angiography, avoiding automatic attribution of every plaque as the cause of pain.
Functional imaging documents ischemia and the territory at risk. Stress echocardiography assesses wall motion, CMR perfusion and scar, SPECT relative distribution, and PET absolute flow and CFR. Selection and thresholds depend on the method; an ischemic percentage is not interchangeable among tests. Exercise ECG measures capacity, symptoms, blood-pressure response, and arrhythmias but is less accurate for stenosis and is uninterpretable with some baseline tracings. Adequate workload is required before an exercise test can be called negative.

Coronary angiography is indicated for severe symptoms, high risk, dysfunction, or strong unresolved suspicion. Visually intermediate stenoses are measured with FFR or iFR before stenting, except with contraindications or unequivocal anatomical evidence in appropriate settings. Physiological pullback distinguishes focal from diffuse gradients and helps predict the benefit of PCI. IVUS and OCT optimize stent sizing, expansion, and apposition, reducing mechanical errors.
With non-obstructive coronary arteries and persistent symptoms, assessment of CFR, microvascular resistance, and acetylcholine response identifies endothelium-independent dysfunction and epicardial or microvascular spasm. Quantitative PET or CMR provides noninvasive alternatives for flow, but invasive testing enables more complete phenotyping. An endotype guides medication and reduces labeling the pain as noncardiac. Testing is performed in expert centers and only when the result changes management.

The final diagnosis should state the presence and extent of disease, functional significance, ventricular function, symptom mechanism, and risk level. “Positive test” without this information is insufficient. Discordance requires assessment of artifacts, probability, diffuse disease, and the microcirculation. Reassessment does not mechanically repeat the same test but selects the method capable of resolving the remaining uncertainty.
Stress CMR combines perfusion, function, and scar without radiation but requires compatibility, patient cooperation, and appropriate gadolinium management. PET measures absolute flow and may distinguish global reduction, although availability is more limited. SPECT has extensive evidence and prognostic value, but attenuation and relative comparison may produce artifacts. Selection does not follow an abstract hierarchy; it identifies the most reliable method for that patient and question.

Invasive assessment entails contrast, radiation, vascular access, and rare coronary complications. Radial access reduces bleeding in many settings, whereas femoral access may be needed for support or large devices. Consent includes the possibility that PCI will not be performed if physiology is negative. Diagnostic coronary angiography must not automatically become treatment before objectives and alternatives have been clarified.

Treatment and prognosis

Smoking cessation is one of the most effective interventions and may require nicotine replacement, varenicline, or bupropion according to contraindications. Aerobic and strength exercise is prescribed progressively. A Mediterranean diet emphasizes vegetables, legumes, whole grains, fish, and unsaturated fats; weight is managed without extreme diets, and rehabilitation increases capacity and adherence. Influenza vaccination and attention to oral and mental health complete a comprehensive preventive approach.
Lipid therapy uses a high-intensity or maximally tolerated statin, with ezetimibe, a PCSK9 inhibitor, or other agents added if LDL remains above the risk-based target. Response is assessed after initiation and periodically. Blood pressure is controlled while avoiding hypotension that worsens perfusion or falls. In diabetes, SGLT2 inhibitors and GLP-1 receptor agonists are selected when indicated for cardiovascular and kidney benefit in addition to glycemic control.

Aspirin is generally used in known atherosclerotic coronary disease; clopidogrel is an alternative in selected settings. After PCI, DAPT duration is proportionate to presentation, complexity, and bleeding risk; combinations are shortened in patients receiving anticoagulation. Dual-pathway therapy with aspirin and vascular-dose rivaroxaban is reserved for selected patients with high ischemic and low bleeding risk. Every intensification requires an explicit indication and a reassessment date.
Antianginal therapy is personalized. Beta-blockers are useful with tachycardia, recent myocardial infarction, arrhythmias, or ventricular dysfunction; calcium channel blockers treat angina and blood pressure and are central in spasm. Long-acting nitrates require a drug-free interval to limit tolerance; ranolazine has little effect on blood pressure and heart rate, but interactions and QT prolongation must be considered; ivabradine requires sinus rhythm and an appropriate heart rate. Response is measured through episodes, activity, and quality of life, not merely the prescribed dose.

PCI improves angina in functionally significant stenoses, but in stable disease it does not provide a universal benefit for death or myocardial infarction over contemporary therapy. Bypass surgery may offer benefit in complex anatomy, left main disease, and selected groups, especially with diabetes or impaired function. A Heart Team compares completeness, durability, risk, and preferences. Consent must clearly separate symptomatic and prognostic benefit and recognize that placebo effects and expectations influence patient-reported outcomes.
Follow-up assesses targets, tolerance, adherence, and new symptoms. Repeated testing without clinical change does not automatically improve outcomes and may lead to unnecessary revascularization. New dyspnea, functional decline, arrhythmia, or heart failure requires ECG, echocardiography, and tests selected for the clinical question. Patients must know how to use nitrate, when to call emergency services, and how to manage medication before procedures, avoiding autonomous discontinuation.

Prognosis is favorable in patients with preserved function, low burden, and controlled factors, but worsens with reduced ejection fraction, left main or multivessel disease, kidney disease, diabetes, and multisite atherosclerosis. Frequent angina affects quality of life and hospital admission more directly than mortality. Residual risk can be reduced but not eliminated. Effective prevention requires continuity over years and adaptation to transitions in age, frailty, and comorbidities.
Blood-pressure control requires balance: high values increase demand and risk, but very low diastolic pressure may reduce coronary perfusion, particularly with stenoses and arterial stiffness. Home and orthostatic measurements guide titration. Heart rate is controlled without causing disabling chronotropic incompetence. Standard targets are adapted to frailty, symptoms, and documented tolerability.

In kidney or liver disease, doses and combinations require review. Some antianginal and antithrombotic drugs accumulate or interact; laboratory monitoring is scheduled after changes. In diabetes, hypoglycemia may mimic or precipitate symptoms and must be prevented. The best therapy is effective and sustainable in the context of comorbidities. Medication reconciliation at every transition reduces errors between hospital and community care.

Complications

Plaque rupture or erosion may cause ACS, myocardial infarction, or sudden death even from a previously nonsevere lesion. The onset of pain at rest or crescendo pain changes the pathway and treatment. Stent thrombosis is rare but serious and is promoted by discontinuation of antiplatelet therapy, underexpansion, and thrombotic factors. Restenosis more often presents with progressive symptoms and requires anatomical and functional demonstration before another procedure.
Ischemic cardiomyopathy results from scar, remodeling, and sometimes ischemia or hibernation. Heart failure, mitral regurgitation, kidney dysfunction, and congestion mutually worsen prognosis. Treatment includes foundational heart-failure drugs and devices when indicated, in addition to coronary assessment. Sudden worsening requires investigation for acute ischemia, arrhythmia, infection, embolism, and adherence problems.

Ventricular arrhythmias may originate from scar; atrial fibrillation is promoted by age, heart failure, and hypertension. Syncope and sustained tachycardia require urgent assessment; isolated premature beats do not define risk without context. Anticoagulation for atrial fibrillation changes the antiplatelet strategy. Bradycardia and conduction block may limit antianginal drugs and require review before considering a pacemaker.
Gastrointestinal or intracranial bleeding increases with combined antithrombotic therapy, age, kidney disease, and anemia. Radial access, the shortest effective duration, gastroprotection in at-risk patients, and blood-pressure control reduce harm. After hemorrhage, the resumption and type of therapy depend on site, hemostasis, indication, and time since stenting. Coordinated decisions avoid both recurrent bleeding and thrombosis from indiscriminate discontinuation.

Persistent angina, deconditioning, and depression may create a cycle of inactivity and hypervigilance. Before angina is defined as refractory, residual stenoses, the microcirculation, spasm, adherence, and noncardiac diagnoses are investigated. Rehabilitation and psychological therapy do not deny ischemia but reduce its functional consequences. Repeated procedures without a physiological target may add complications without improving symptoms.
Systemic atherosclerosis causes stroke, peripheral artery disease, and aneurysms; kidney disease and diabetes amplify risk. Multiple drugs may cause hypotension, bradycardia, electrolyte abnormalities, and falls. Follow-up must reconcile prescriptions from multiple specialists and simplify them when possible. Optimal prevention balances intensity with actual sustainability for the patient.

Complications of revascularization include restenosis, thrombosis, bleeding, stroke, kidney injury, and, after bypass surgery, infection, atrial fibrillation, and graft problems. Imaging and technique reduce but do not eliminate risk; the initial choice also considers the likelihood of future procedures. Symptom control is not interpreted as cure of atherosclerosis and requires continuing prevention.
Disease may impair sexual health through ischemia, fear, depression, and medication. Erectile dysfunction shares vascular risk factors and may precede other manifestations. Treatment respects the absolute contraindication between nitrates and PDE5 inhibitors; explicit discussion prevents autonomous discontinuation or dangerous combinations. Sexual activity is resumed according to stability and functional capacity, not prohibited indefinitely.